Drug intelligence / Profile preview

RGC-1503

Development stage: Unknown
Lead developer: Rgene

Overview

Experimental oncology drug candidate from Rgene Corporation being guided through development by ABVC BioPharma’s subsidiary (BioKey) under a Clinical Development Service Agreement; designated for treatment of colorectal cancer through completion of Phase II clinical studies under U.S. FDA IND requirements. Specific target, modality, and mechanism of action have not been publicly disclosed in the cited materials.[1][9][7][3]

Beyond the preview

Go deeper on RGC-1503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGC-1503.

Explore the full profile